Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme

Regueiro, Miguel; Siegmund, Britta; Yarur, Andrés; Steinwurz, Flávio; Gecse, K; Goetsch, Martina; Bhattacharjee, Abhishek; Wu, Joseph; Green, Jesse; McDonnell, Aoibhinn; Crosby, Catherine; Lazin, Krisztina; Branquinho, Diogo; Modesto, Irene; T. Abreu, María

doi:10.1093/ecco-jcc/jjae060

Public

Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme

Published in Journal of Crohn s and Colitis • May 3, 2024

Authors:

Miguel Regueiro

Britta Siegmund

Andrés Yarur

Abstract

BACKGROUND AND AIMS: Infections are a safety concern in patients with ulcerative colitis [UC]. Etrasimod is an oral, once daily [QD], selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active UC. It leads to selective and reversible lymphocyte...

View

Open Access

Subject

Medicine

Ulcerative colitis

Internal medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!